Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Dianthus Therapeutics (Nasdaq: DNTH) will host a conference call and webcast on March 9, 2026 at 8:00 a.m. ET to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) will host a conference call and webcast on March 9, 2026 at 8:00 a.m. ET to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.

Live access is available by phone with pre-registration and via the investor webcast at https://investor.dianthustx.com/. A replay will be posted following the call.

Argus Mar 9 session

+21.52% close to close 6.5x rel. volume Open Argus

Details

News Market Reaction – DNTH

On Mar 9, the first trading day after this news, DNTH closed 21.52% above the previous close. That session’s volume was 6.5x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Mar 9 session.

Key Figures

Conference call time: 8:00 a.m. ET Trial phase: Phase 3

Conference call time

8:00 a.m. ET

Scheduled for March 9, 2026 to discuss interim responder analysis

Trial phase

Phase 3

CAPTIVATE trial of claseprubart in CIDP, Part A interim analysis

Previous Conferences,clinical trial Reports

1 past event · Latest: Sep 07

Same Type 1 event

1. Sep 07

   Conference clinical update

   24h Move

   +20.0%

   Announced call to discuss Phase 2 MaGic trial results for claseprubart.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

chronic inflammatory demyelinating polyneuropathy, cidp, phase 3

3 terms

chronic inflammatory demyelinating polyneuropathy medical

"Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long‑term autoimmune disorder in which the body attacks the protective coating (myelin) around peripheral nerves, causing progressive weakness, numbness and poor coordination. Think of myelin as insulation on electrical wires: when it is damaged, nerve signals slow or fail. CIDP matters to investors because it drives demand for ongoing medical treatments, costly therapies and clinical trials, and outcomes or approvals can significantly affect companies developing drugs or devices for the disease.

cidp medical

"claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow"

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long‑term autoimmune disorder in which the immune system progressively damages the protective coating (myelin) around peripheral nerves, causing weakness, numbness and reduced coordination — like frayed insulation on electrical wiring that disrupts signal flow. It matters to investors because treatments, clinical trial results, regulatory approvals and reimbursement decisions directly affect demand, pricing and revenue prospects for companies developing therapies for this disabling condition.

phase 3 medical

"interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET.

Investor Conference Call & Webcast Information
To access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN. 

The live webcast may be accessed via the Investors section of the Dianthus Therapeutics website at https://investor.dianthustx.com/. A replay of the webcast will be available following the call.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the Dianthus (DNTH) conference call to discuss CAPTIVATE interim results?

The conference call is scheduled for March 9, 2026 at 8:00 a.m. ET. According to the company, the call will review interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.

How can investors access the DNTH March 9, 2026 webcast and replay?

Investors can access the live webcast via the Dianthus investor website at the provided URL. According to the company, a replay of the webcast will be available on the investor site after the conference call concludes.

Do I need to register to join the Dianthus (DNTH) investor conference call by phone?

Yes, phone participants must pre-register to receive a dial-in number and personal PIN. According to the company, registration is required for the question-and-answer session and access to the live phone line.

What will Dianthus (DNTH) discuss during the March 9, 2026 CAPTIVATE call?

The company will discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial. According to the company, the presentation will focus on responder data for claseprubart in patients with CIDP.

Where can I find materials or slides from the DNTH CAPTIVATE interim results call?

Presentation materials and any supplemental disclosures are typically posted on the investor relations website. According to the company, investors should check the Dianthus investor site for slides, replays, and related documents after the call.